TY - JOUR
T1 - Plasma KIM-1 is associated with recurrence risk after nephrectomy for localized renal cell carcinoma
T2 - A trial of the ECOG-ACRIN research group (E2805)
AU - Xu, Wenxin
AU - Puligandla, Mäneka
AU - Halbert, Brian
AU - Haas, Naomi B.
AU - Flaherty, Keith T.
AU - Uzzo, Robert G.
AU - Dutcher, Janice P.
AU - DiPaola, Robert S.
AU - Sabbisetti, Venkata
AU - Bhatt, Rupal S.
N1 - ©2021 American Association for Cancer Research.
PY - 2021/6
Y1 - 2021/6
N2 - PURPOSE: No circulating biomarkers are currently available to identify patients at highest risk of recurrence after nephrectomy for renal cell carcinoma (RCC). Kidney injury molecule-1 (KIM-1) is overexpressed in RCC and its ectodomain circulates in plasma. We investigated whether plasma KIM-1 is a prognostic biomarker in patients with localized RCC after nephrectomy.EXPERIMENTAL DESIGN: The ECOG-ACRIN E2805 (ASSURE) trial evaluated adjuvant sunitinib, sorafenib, or placebo in resected high-risk RCC. KIM-1 levels were measured from banked plasma at trial enrollment 4-12 weeks after nephrectomy. Lognormal accelerated failure time models were used to test for association between KIM-1 and disease-free survival (DFS) as well as overall survival (OS).RESULTS: Plasma from 418 patients was analyzed. Higher post-nephrectomy KIM-1 was associated with worse DFS across all study arms after adjustment for Fuhrman grade, T stage, N stage, and tumor histology [survival time ratio 0.56 for 75th vs. 25th percentile of KIM-1; 95% confidence interval (CI), 0.42-0.73;
P < 0.001]. The association between KIM-1 and DFS was stronger among patients with pathologic nodal involvement (
P
interaction = 0.0086). The addition of post-nephrectomy KIM-1 improved the concordance of clinical prognostic models [Stage, Size, Grade, and Necrosis (SSIGN) concordance 0.57 vs. 0.43,
P = 0.05; UCLA International Staging System (UISS) concordance 0.60 vs. 0.40,
P = 0.0005]. Higher post-nephrectomy KIM-1 was also associated with worse OS after multivariable adjustment (survival time ratio 0.71 for 75th vs. 25th percentile of KIM-1; 95% CI, 0.56-0.91;
P < 0.001).
CONCLUSIONS: Post-nephrectomy plasma KIM-1 is associated with DFS and OS in RCC, and may be a biomarker for microscopic residual disease.
AB - PURPOSE: No circulating biomarkers are currently available to identify patients at highest risk of recurrence after nephrectomy for renal cell carcinoma (RCC). Kidney injury molecule-1 (KIM-1) is overexpressed in RCC and its ectodomain circulates in plasma. We investigated whether plasma KIM-1 is a prognostic biomarker in patients with localized RCC after nephrectomy.EXPERIMENTAL DESIGN: The ECOG-ACRIN E2805 (ASSURE) trial evaluated adjuvant sunitinib, sorafenib, or placebo in resected high-risk RCC. KIM-1 levels were measured from banked plasma at trial enrollment 4-12 weeks after nephrectomy. Lognormal accelerated failure time models were used to test for association between KIM-1 and disease-free survival (DFS) as well as overall survival (OS).RESULTS: Plasma from 418 patients was analyzed. Higher post-nephrectomy KIM-1 was associated with worse DFS across all study arms after adjustment for Fuhrman grade, T stage, N stage, and tumor histology [survival time ratio 0.56 for 75th vs. 25th percentile of KIM-1; 95% confidence interval (CI), 0.42-0.73;
P < 0.001]. The association between KIM-1 and DFS was stronger among patients with pathologic nodal involvement (
P
interaction = 0.0086). The addition of post-nephrectomy KIM-1 improved the concordance of clinical prognostic models [Stage, Size, Grade, and Necrosis (SSIGN) concordance 0.57 vs. 0.43,
P = 0.05; UCLA International Staging System (UISS) concordance 0.60 vs. 0.40,
P = 0.0005]. Higher post-nephrectomy KIM-1 was also associated with worse OS after multivariable adjustment (survival time ratio 0.71 for 75th vs. 25th percentile of KIM-1; 95% CI, 0.56-0.91;
P < 0.001).
CONCLUSIONS: Post-nephrectomy plasma KIM-1 is associated with DFS and OS in RCC, and may be a biomarker for microscopic residual disease.
KW - Carcinoma, Renal Cell/drug therapy
KW - Chemotherapy, Adjuvant
KW - Disease-Free Survival
KW - Humans
KW - Kidney Neoplasms/drug therapy
KW - Nephrectomy/adverse effects
KW - Prognosis
KW - Sunitinib/therapeutic use
UR - http://www.scopus.com/inward/record.url?scp=85107975579&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000662291200016&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1158/1078-0432.CCR-21-0025
DO - 10.1158/1078-0432.CCR-21-0025
M3 - Article
C2 - 33832947
SN - 1078-0432
VL - 27
SP - 3397
EP - 3403
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 12
ER -